CRDF

Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes

Cardiff Oncology: Current Slump Doesn't Look Right

Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?

Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference

Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates